Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | GPR4 | P46093 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983802 | 0.95 | CNR1 (0.43) | CNR1CNR2GPR4EPHX2RET | |
| SCHEMBL30983893 | 0.92 | CNR1 (0.42) | CNR1CNR2GPR4EPHX2PIK3CD | |
| SCHEMBL30983922 | 0.92 | CNR1 (0.39) | CNR1CNR2ADORA2AGPR4EPHX2 | |
| SCHEMBL30983856 | 0.91 | CNR1 (0.41) | CNR1CNR2GPR4EPHX2RET | |
| SCHEMBL30983947 | 0.90 | ADORA2A (0.45) | CNR1CNR2ADORA2AGPR4EPHX2 | |
| SCHEMBL30983841 | 0.89 | CNR1 (0.41) | CNR1CNR2GPR4EPHX2RET | |
| SCHEMBL30983836 | 0.89 | CNR1 (0.41) | CNR1CNR2GPR4EPHX2RET | |
| SCHEMBL30984030 | 0.89 | PIK3CD (0.45) | CNR1CNR2ADORA2APIK3CD | |
| SCHEMBL30983428 | 0.89 | KMT2A (0.43) | CNR1MAPK1SMN1; SMN2 | |
| SCHEMBL30983895 | 0.87 | CNR1 (0.37) | CNR1CNR2GPR4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |